Canagliflozin heMihydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Canagliflozin, an orally active and selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, was co-developed by Mitsubishi Tanabe Pharma and Johnson & Johnson (J&J) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The drug was approved in March by the U.S. FDA and launched in April 2013 in the U.S. SGLT2 is involved in the glucose re-absorption pathway in the kidney, and its inhibition increases urinary glucose excretion, and reduces plasma glucose and HbA1c levels. In addition, canagliflozin is safe in combination with other commonly used antidiabetic agents and has a significant effect on body weight reduction. A recently published process patent from ScinoPharm Taiwan describes the synthesis of canagliflozin.

Verwenden

Canagliflozin Hemihydrate is a derivative of Canagliflozin (C175190), which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.

Synthese

Synthesis of the aglycone region of canagliflozin was described in a separate patent by first condensing commercially available 5- bromo-2-methylbenzoyl chloride (14) and 2-(4-fluorophenyl)- thiophene (15) under Friedel¨CCrafts acylation conditions to give ketone 16 in 69% yield as a crystalline solid. Ketone 16 was then reduced with triethylsilyl hydride in the presence of BF3Et2O at low temperature to give aglycone bromide 17 in 70% yield. The precursor for the glycoside moiety, commercially available glycoside triol 18, was selectively treated with t-butyldiphenylsilyl chloride (TBDPSCl) in THF in the presence of imidazole to give the bis-silyl ether 19 in 81% yield. Next, a unique, stereospecific b-C-arylglucosidation was developed to secure the union of the aglyone- and glycoside-containing portions of canagliflozin. Bromide 17 was subjected to magnesium powder under standard Grignard conditions prior to treatment with AlCl3 in THF in situ. This resulting mixture was then exposed to a solution of compound 19 in PhOMe which had been pre-treated with n-BuLi, and the entire mixture was then warmed to 150 ?? for 5 h to ultimately give the b-anomer 20 in 56% yield. Finally, removal of the silyl groups within 20 with tetrabutyl ammonium fluoride (TBAF) in THF delivered canagliflozin hydrate (III) in 73% yield.

Canagliflozin heMihydrate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Canagliflozin heMihydrate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Cangzhou Kangrui Pharma Tech Co. Ltd.,	+86-18632776803 +86-13833998158	cangzhoukangrui@126.com	China	733	58
Hebei Mojin Biotechnology Co., Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12825	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	375	58
Shanghai Daken Advanced Materials Co.,Ltd	+86-371-66670886	info@dakenam.com	China	18648	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21639	55
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9218	55
Nanjing ChemLin Chemical Industry Co., Ltd.	025-83697070	product@chemlin.com.cn	CHINA	3009	60
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32820	60
Anqing Chico Pharmaceutical Co., Ltd.	15380796838	chloewu@chicopharm.cn	CHINA	340	58

---

• Canagliflozin hydrate (2:1)
• Canagliflozin heMihydrate
• D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, hydrate (2:1)
• Canagliflozin heMihydrates
• (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hydrate (2:1)
• Cageline
• Invokana hemihydrate
• JNJ 28431754 hemihydrate
• JNJ28431754 hemihydrate
• JNJ-28431754 hemihydrate
• JNJ28431754 HEMIHYDRATE; JNJ-28431754 HEMIHYDRATE; JNJ 28431754 HEMIHYDRATE; TA-7284 HEMIHYDRATE; TA7284 HEMIHYDRATE; INVOKANA HEMIHYDRATE
• TA7284 hemihydrate
• TA-7284 hemihydrate
• bis((2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thio phen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymet hyl)oxane-3,4,5-triol) hydrate
• Canagliflozin (API)
• Canagli ozin Hemi hydrate
• (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol Hemihydrate
• Canagliflozin hemihydrate (JNJ 28431754)
• TIANFU-CHEM 928672-86-0 Canagliflozin heMihydrate
• NSC 36678
• NSC 406879
• Cagliflozin heMihydrate
• (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Hemihydrate
• Canagliflozin hydrate
• Kaglie net semihydrate
• (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol hydrate
• Kagliflozin
• CANIGLAFOZIN HEMIHYDRATE
• 928672-86-0
• 2C24H25FO5SH2O
• C24H25FO5SH2O
• C24H25FO5S12H2O
• Canagliflozin
• API
• 928672-86-0